Kolon TissueGene FY 2025 Annual ReportBeta
Kolon TissueGene annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Kolon TissueGene FY 2025 Annual Report Analysis
Business Overview
- • Core revenue: 100% from Complex Distribution business (Health Beauty and Liquor Beverage), Bio segment (TG-C gene therapy) reported no sales in FY2025
- • FDA Clinical Hold on TG-C Knee OA Phase 3 lifted in April 2020; Phase 3 patient enrollment completed with 1,066 patients as of July 2024, follow-up ongoing
Management Discussion & Analysis
- • Revenue USD 3,627K (-2.5% YoY); Operating loss USD 15,696K (-2.7% improvement); Net loss USD 135,413K (-446.5%)
- • Bio segment operating loss improved 7.1% to USD (13,898)K due to reduced legal and SG&A expenses
Risk Factors
- • Foreign currency monetary assets/liabilities negligible at fiscal year-end, foreign exchange impact on profit/loss insignificant
- • Variable interest rate borrowings zero at fiscal year-end, no exposure to interest rate fluctuation risk
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding